Cantor Fitzgerald Reiterates Overweight Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They presently have a $13.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the stock. Truist Financial restated a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.25.

Marinus Pharmaceuticals Stock Performance

Shares of Marinus Pharmaceuticals stock traded up $0.03 on Monday, hitting $1.53. 268,153 shares of the company’s stock were exchanged, compared to its average volume of 1,136,712. The company has a 50-day simple moving average of $1.35 and a 200-day simple moving average of $3.06. The stock has a market capitalization of $84.00 million, a PE ratio of -0.58 and a beta of 1.13. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter in the prior year, the business earned ($0.61) EPS. As a group, equities analysts anticipate that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. Avoro Capital Advisors LLC lifted its holdings in Marinus Pharmaceuticals by 31.4% during the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after purchasing an additional 990,607 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at about $813,000. Renaissance Technologies LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at about $727,000. Superstring Capital Management LP acquired a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $5,027,000. Finally, XTX Topco Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at about $232,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.